论文部分内容阅读
[目的]观察舒洛地特治疗2型糖尿病肾病微量白蛋白尿的疗效。[方法]纳入2型糖尿病肾病微量白蛋白尿期患者42例,随机分为舒洛地特治疗组(22例)及对照组(20例),两组原降糖降压等药物治疗不变,治疗组加用舒洛地特治疗12周。观察尿微量白蛋白变化情况及糖代谢指标、血肌酐、凝血指标及不良反应。[结果]治疗组尿微量白蛋白随时间逐渐下降,至第8周已较治疗前有明显统计学差异,至第12周下降达29.6%,两组糖化血红蛋白、血肌酐、血凝指标、血压水平无统计学差异。[结论]舒洛地特可有效降低2型糖尿病肾病微量白蛋白尿排泄率。
[Objective] To observe the curative effect of sulodentia on type 2 diabetic nephropathy microalbuminuria. [Methods] 42 patients with type 2 diabetic nephropathy with microalbuminuria were randomly divided into sulodexide treatment group (n = 22) and control group (n = 20) , Treatment group with sulodexide for 12 weeks. Urinary microalbuminuria and glucose metabolism indicators, serum creatinine, coagulation parameters and adverse reactions were observed. [Results] The urinary albumin in the treatment group decreased gradually with time. By the 8th week, the urinary albumin had a significant difference compared with that before treatment, and dropped to 29.6% by the 12th week. The two groups of HbA1c, serum creatinine, blood coagulation index No significant difference in level. [Conclusion] Schulutide can effectively reduce the microalbuminuria excretion rate of type 2 diabetic nephropathy.